Reduced expression of the CDK inhibitor p27(KIP1) in rat two-stage bladder carcinogenesis and its association with expression profiles of p21(WAF1/Cip1) and p53

Carcinogenesis

Volumn 20, Issue 9, 1999, Pages 1697-1708

  Lee, Chyi Chia R ^a,b   Ichihara, Toshio ^a   Yamamoto, Shinji ^a   Wanibuchi, Hideki ^a   Sugimura, Kazunobu ^a   Wada, Seiji ^a   Kishimoto, Taketoshi ^a   Fukushima, Shoji ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CYCLIN DEPENDENT KINASE; CYCLINE; MESSENGER RNA; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE MUTATION; GROWTH INHIBITION; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MESSENGER RNA SYNTHESIS; NONHUMAN; PAPILLOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

ANIMALS; ASCORBIC ACID; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE PROTEINS; CELL DIVISION; COCARCINOGENESIS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HYPERPLASIA; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PAPILLOMA; RATS; RATS, INBRED F344; RNA, MESSENGER; RNA, NEOPLASM; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0032821617     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/20.9.1697     Document Type: Article

References (81)

1. Wang, T.C., Cardiff, R.D., Zukerberg, L.R., Lees, E., Arnold, A. and Schmidt, E.V. (1994) Mammary hyperplasia and carcinoma in MMTV-cyclin D1 (PRAD-1) transgenic mice. Nature, 369, 669-671.
2. Mueller, A., Odze, R., Jenkins, T.D., Shahsesfaei, A., Nakagawa, H., Inomoto, T. and Rustgi, A.K. (1997) A transgenic mouse model with cyclin D1 overexpression results in cell cycle, epidermal growth factor receptor, and p53 abnormalities. Cancer Res., 57, 5542-5549.
3. Bianchi, A.B., Fischer, S.M., Robles, A.J., Rinchik, E.M. and Conti, C.J. (1993) Overexpression of cyclin D1 in mouse skin carcinogenesis. Oncogene, 8, 781-786.
4. Lee, C.C.R., Yamamoto, S., Wanibuchi, H., Wada, S., Sugimura, K., Kishimoto, T. and Fukushima, S. (1997) Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation. Cancer Res., 57, 4765-4776.
5. Ito, N., Hiasa, Y., Tamai, A., Okajima, E. and Kitamura, H. (1969) Histogenesis of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats. Gann, 60, 401-410.
6. Cohen, S.M., Arai, M., Jacobs, J.B. and Friedell, G.H. (1979) Promoting effect of saccharin and DL-tryptophan in urinary bladder carcinogenesis. Cancer Res., 39, 1207-1217.
7. Fukushima, S., Imaida, K., Sakata, T., Okamura, T., Shibata, M. and Ito, N. (1983) Promoting effects of sodium L-ascorbate on two-stage urinary bladder carcinogenesis in rats. Cancer Res., 43, 4454-4457.
8. Fukushima, S., Tanaka, H., Asakawa, E., Kagawa, M., Yamamoto, A. and Shirai, T. (1992) Carcinogenicity of uracil, a nongenotoxic chemical in rats and mice and its rationale. Cancer Res., 53, 1675-1680.
9. Pipit, H.C. an Dragan, Y. (1995) Chemical carcinogenesis. In Klaassen, C.D. (ed.) Casarett & Doull's Toxicology: The Basic Science of Poison. McGraw-Hill, New York, NY, pp. 201-267.
10. Cohen, S.M. and Ellwein, L.B. (1990) Cell proliferation in carcinogenesis. Science, 249, 1007-1011.
11. Cohen, S.M. and Ellwein, L.B. (1991) Genetic errors, cell proliferation, and carcinogenesis. Cancer Res., 51, 6493-6505.
12. Serrano, M., Hannon, G.J. and Beach, D. (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D1/CDK4. Nature, 366, 704-707.
13. Nobori, T., Miura, K., Wu, D.J., Lois, A., Takabayashi, K. and Carson, D. (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753-756.
14. Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S.V., Stockert, E., Day, R.S.III, Johnson, B.E. and Skolnick, M.H. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440.
15. Hannon, G.J. and Beach, D. (1994) p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature, 371, 257-261.
16. Gu, Y., Turck, C.W. and Morgan, D.O. (1993) Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature, 366, 707-710.
17. CIP1 CDK inhibitor family, is a candidate tumor suppressor gene. Genes Dev., 9, 650-662.
18. Xiong, Y., Hannom, G.J., Zhang, H., Gasso, D., Kobayashi, R. and Beach, D. (1993) p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704.
19. 1 cyclin-dependent kinases. Cell, 75, 805-816.
20. El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W. and Vogelstein, B. (1993) WAFl, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
21. 1 cyclin-CDK protein kinase activity, is related to p21. Cell, 78, 67-74.
22. Hunter, T. and Pines, J. (1994) Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79, 573-582.
23. 1 cyclin-dependent kinases. Genes Dev., 9, 1149-1163.
24. KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78, 59-66.
25. KIP1, a cyclin-CDK inhibitor, links transforming growth factor-B and contact inhibition to cell cycle arrest. Genes Dev., 8, 9-22.
26. Steeg, P.S. and Abrams, J.S. (1997) Cancer prognostics: past, present and p27. Nature Med., 3, 152-154.
27. KIP1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med., 3, 222-225.
28. KIP1 protein: prognostic implications in primary breast cancer. Nature Med., 3, 227-230.
29. Tan, P., Cady, B., Wanner, M., Worland, P., Cukor, B., Magi-Gulluzzi, C., Lavin, P., Draetta, G., Pagano, M. and Loda, M. (1997) The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res., 57, 1259-1263.
30. Loda, M., Cukor, B., Tam, S.W., Lavin, P.F., Fiorentino, M., Draetta, G.F., Jessup, J.M. and Pagano, M. (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinoma. Nature Med., 3, 231-234.
31. KIP1 in multistage colorectal carcinogenesis. Cancer Res., 58, 114-122.
32. Mori, M., Mimori, K., Shiraishi, T., Tanaka, S., Ueo, H., Sugimachi, K. an Akiyoshi, T. (1997) p27 expression and gastric carcinoma. Nature Med., 3, 593.
33. Esposito, V., Baldi, A., De Luca, A., Groger, A.M., Loda, M., Giordano, G.G., Caputi, M., Baldi, F., Pagano, M. and Giordano, A. (1997) Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res., 57, 3381-3385.
34. KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res., 58, 1042-1047.
35. Kipl expression in nontumorous and neoplastic human pituitaries. Am. J. Pathol., 151, 509-519.
36. Dahia, P.L., Aguiar, R.C., Honegger, J., Fahlbush, R., Jordan, S., Lowe, D.G., Lu, X., Clayton, R.N., Besser, G.M. and Grossman, A.B. (1998) Mutation and expression analysis of p27/Kipl gene in corticotrophin-secreting tumours. Oncogene, 16, 69-76.
37. Kipl and Ki-67 in benign and malignant thyroid tumors. Mod. Pathol., 11, 169-174.
38. Kipl in prostatic adenocarcinoma. Mod. Pathol., 11, 324-328.
39. Kipl levels with recurrence and survival in patients with stage C prostate carcinoma. J. Natl Cancer Inst., 90, 916-920.
40. Kipl is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res., 58, 542-548.
41. Jordan, R.C., Bradley, G. and Slingerland, J. (1998) Reduced levels of the cell-cycle inhibitor p27kipl in epithelial dysplasia and carcinoma of the oral cavity. Am. J. Pathol., 152, 585-590.
42. Singh, S.P., Lipman, J., Goldman, H., Ellis, F.H.Jr, Aizenman, L., Cangi, M.G., Signoretti, S., Chiaur, D.S., Pagano, M. and Loda, M. (1998) Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res., 58, 1730-1735.
43. kipl chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res., 55, 1211-1214.
44. Kawamata, N., Morosetti, R., Miller, C.W., Park, D., Spirin, K.S., Nakamaki, T., Takeuchi, S., Hatta, Y., Simpson, J., Wilczynski, S., Lee, Y.Y., Bartram, C.R. and Koeffler, H.P. (1995) Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kipl in human malignancies. Cancer Res., 55, 2266-2269.
45. Kipl in primary breast carcinomas. Hum. Genet., 97, 91-94.
46. Kipl mutation found in breast cancer. Cancer Res., 56, 2400-2404.
47. Fukushima, S., Murasaki, G., Hirose, M., Nakanishi, K., Hasegawa, R. and Ito, N. (1982) Histopathological analysis of preneoplastic changes during N-butyl-N-(4-hydroxybutyl)nitrosamine induced urinary bladder carcinogenesis in rats. Acta Pathol. Jpn, 32, 234-250.
48. Otori, K., Yano, Y., Takada, N., Lee, C.C.R., Hayashi, S., Otani, S. and Fukushima, S. (1997) Reversibility and apoptosis in rat urinary bladder papillomatosis induced by uracil. Carcinogenesis, 18, 1485-1489.
49. WAF1/Cip1, cyclin D1 and PCNA in a mixed transitional cell carcinoma and adenocarcinoma of the renal pelvis: a case report. Jpn J. Clin. Oncol., 28, 227-232.
50. Lee, C.C.R., Yamamoto, S., Morimura, K., Wanibuchi, H., Nishisaka, N., Ikemoto, S., Nakatani, T., Wada, S., Kishimoto, S. and Fukushima, S. (1997) Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer. 79, 780-789.
51. Kipl expression in endocrine and other tumors. Am. J. Pathol., 150, 401-407.
52. Chomczynski, P. (1993) A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Focus, 15, 532-536.
53. Sugimura, K., Lee, C.C.R., Kim, T., Goto, T., Kasai, S., Harimoto, K., Yamagami, S. and Kishimoto, T. (1997) Production of hepatocyte growth factor is increased in chronic renal failure. Nephron, 75, 7-12.
54. Orita, M., Suzuki, Y., Sekiya, T. and Hayashi, K. (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5, 874-879.
55. Masui, T., Don, I., Takada, N., Ogawa, K., Shirai, T. and Fukushima, S. (1994) p53 mutations in early neoplastic lesions of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis, 15, 2379-2381.
56. Lipponen, P.K. and Eskelinen, M.J. (1992) Cell proliferation of transitional cell bladder tumors determined by PCNA/cyclin immunostaining and its prognostic value. Br. J. Cancer, 66, 171-176.
57. Pagano, M., Tam, S.W., Theodoras, A.M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P.R., Draetta, G.F. and Rolfe, M. (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science, 271, 682-685.
58. Kipl accumulation during the cell cycle. Science, 271, 1861-1864.
59. KIPI is haplo-insufficient for tumour suppression. Nature, 396, 177-180.
60. 1 arrest. Cell, 76, 1013-1023.
61. Waga, S., Hannon, G.J., Beach, D. and Stillman, B. (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature, 369, 574-579.
62. WAF1/CIP1 on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene, 13, 1395-1403.
63. Yang, Z.-Y., Perkins, N.D., Ohno, T., Nabel, E.G. and Nabel, G.J. (1995) The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Med., 1, 1053-1056.
64. Malkowics, S.B., Tomaszewski, J.E., Linnenbach, A.J., Cangiano, T.A., Maruta, Y. and McGarvey, T.W. (1996) Novel p21 mutations in superficial and invasive transitional carcinomas. Oncogene, 13, 1831-1837.
65. WAF1/CIP1 in primary bladder tumors. Oncol. Res., 8, 409-414.
66. WAF1/CIP1 and p53 gene alterations. Int. J. Cancer, 68, 501-505.
67. Levin, J.A. (1997) p53, the cellular gatekeeper for growth and division. Cell, 88, 323-331.
68. Hollstein, M., Rice, K., Greenblatt, M.S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-Sorensen, B., Montesano, R. and Harris, C.C. (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res., 22, 3551-3555.
69. Levine, A.J., Momand, J. and Finlay, C.A. (1991) The p53 tumor suppressor gene. Nature, 351, 453-456.
70. Spruck, C.H.III, Ohneseit, P.F., Gonzalez-Zulueta, M. et al. (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54, 784-788.
71. Esrig, D., Spruck, C.H.III, Nichols, P.W., Chaiwun, B., Steven, K., Groshen, S., Chen, S.C., Skinner, D.G., Jones, P.A. and Cote, R.J. (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol., 143, 1389-1397.
72. Esrig, D., Elmajian, D., Groshen, S., Freeman, J.A., Stein, J.P., Chen, S.C., Nichols, P.W., Skinner, D.G., Jones, P.A. and Cote, R.J. (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Eng. J. Med., 331, 1259-1265.
73. Habuchi, T., Ogawa, O., Kakehi, Y., Ogura, K., Koshiba, M., Sugiyama, T. and Yoshida, O. (1992) Allelic loss of chromosome 17p in urothelial cancer: strong association with invasive phenotype. J. Urol., 148, 1595-1599.
74. Asamoto, M., Mann, A.M. and Cohen, S.M. (1994) p53 mutation is infrequent and might not give a growth advantage in rat bladder carcinogenesis in vivo. Carcinogenesis, 15, 455-458.
75. Okamoto, M., Hattori, K., Fujimoto, K., Tanaka, Y., Gloosby, C.L. and Oyasu, R. (1998) Antisense RNA-mediated reduction of p53 induces malignant phenotype in nontumorigenic rat urothelial cells. Carcinogenesis, 19, 73-79.
76. WAF1/Cipl expression by p53-independent pathways. Oncogene, 12, 1557-1564.
77. Kipl and degree of malignancy in human breast and colorectal cancers. Proc. Natl Acad. Sci. USA, 10, 6380-6385.
78. KIP1 display increased body size, multiple organ hyperplasia, retina dysplasia, and pituitary tumors. Cell, 85, 707-721.
79. Kipl deficient mice. Cell, 85, 733-744.
80. KIP1. Cell, 85, 721-732.
81. KIP1 expression is inversely proportional to the proliferative index. Am. J. Pathol., 151, 151-160